Patents by Inventor Chunqiu Lai
Chunqiu Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399340Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: October 12, 2022Publication date: December 14, 2023Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Andreas Kling, Frauke Pohlki, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Michael Michaelides
-
Publication number: 20230183261Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: February 3, 2022Publication date: June 15, 2023Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
-
Publication number: 20220259226Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: April 22, 2022Publication date: August 18, 2022Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Yujia Dai, Jane Gong, Roberto Risi, Yiyun Yu, Guidong Zhu
-
Publication number: 20210292339Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: October 23, 2020Publication date: September 23, 2021Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU
-
Publication number: 20200325153Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: May 11, 2020Publication date: October 15, 2020Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
-
Publication number: 20200255451Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: August 15, 2018Publication date: August 13, 2020Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU, Dominique POTIN, Fabrice Guillier
-
Publication number: 20200239494Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: August 15, 2018Publication date: July 30, 2020Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Michael Michaelides
-
Patent number: 10676485Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: GrantFiled: August 15, 2018Date of Patent: June 9, 2020Assignee: AbbVie Inc.Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Zhi-Fu Tao, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Thomas D. Penning
-
Publication number: 20200010480Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: September 18, 2019Publication date: January 9, 2020Applicant: AbbVie Inc.Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
-
Publication number: 20190144465Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).Type: ApplicationFiled: August 15, 2018Publication date: May 16, 2019Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
-
Publication number: 20190055264Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: August 15, 2018Publication date: February 21, 2019Inventors: Patrick B. Brady, Wilfried Braje, Yujia Dai, George A. Doherty, Jane Gong, Katja Jantos, Cheng Ji, Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Anthony Mastracchio, Roberto M. Risi, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Xilu Wang, Michael D. Wendt, Yiyun Yu, Guidong Zhu, Thomas D. Penning
-
Patent number: 9796708Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).Type: GrantFiled: March 13, 2014Date of Patent: October 24, 2017Assignee: AbbVie Inc.Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iguturi, Madhu Babu Dabbeeru
-
Patent number: 9718821Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.Type: GrantFiled: February 22, 2013Date of Patent: August 1, 2017Assignee: AbbVie Inc.Inventors: Keith W. Woods, Anthony Mastracchio, Chunqiu Lai, Viraj B. Gandhi, Thomas D. Penning
-
Patent number: 9650358Abstract: Disclosed are compound of Formula (Ia), wherein R2, R12, R16, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).Type: GrantFiled: March 13, 2014Date of Patent: May 16, 2017Assignee: AbbVie Inc.Inventors: Anthony Mastracchio, Milan Bruncko, Chunqiu Lai, Julie M. Miyashiro, Zhi-Fu Tao, Keith W. Woods, Thomas D. Penning, Andrew J. Souers
-
Patent number: 9328112Abstract: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).Type: GrantFiled: December 12, 2014Date of Patent: May 3, 2016Assignee: AbbVie Inc.Inventors: Robin Frey, Jane Gong, Zhiqin Ji, Chunqiu Lai, Thomas Penning, Xiaohong Song, Andrew Souers, Yunsong Tong, Gui-Dong Zhu
-
Publication number: 20160060257Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).Type: ApplicationFiled: March 13, 2014Publication date: March 3, 2016Applicant: ABBVIE INC.Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iquturi, Madhu Babu Dabbeeru
-
Patent number: 9181239Abstract: Compounds of formula (I), and pharmaceutical acceptable salts thereof, which inhibit the activity of kinases such as Wee-1 kinase are described. Also described are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.Type: GrantFiled: October 18, 2012Date of Patent: November 10, 2015Assignee: AbbVie Inc.Inventors: Anthony Mastracchio, Chunqiu Lai, Thomas D. Penning
-
Patent number: 9181246Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.Type: GrantFiled: July 28, 2014Date of Patent: November 10, 2015Assignee: AbbVie Inc.Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Alan S. Florjancic, Yunsong Tong
-
Publication number: 20150218165Abstract: Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).Type: ApplicationFiled: December 12, 2014Publication date: August 6, 2015Applicant: ABBVIE INC.Inventors: Robin Frey, Jianchun Gong, Zhiqin JI, Chunqiu Lai, Thomas Penning, Xiaohong Song, Andrew Souers, Yunsong Tong, Gui-Dong Zhu
-
Patent number: 9051327Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein B, R1, R2, R4, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.Type: GrantFiled: June 18, 2014Date of Patent: June 9, 2015Assignee: AbbVie Inc.Inventors: Gui-Dong Zhu, Jane Gong, Andrew S. Judd, Virajkumar B. Gandhi, Alexander R. Shoemaker, Thomas D. Penning, Michael R. Michaelides, Chunqiu Lai, Keith W. Woods